Literature DB >> 28127041

Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.

Michael T Nurmohamed1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28127041     DOI： 10.1038/nrrheum.2017.4

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  7 in total

1.  Tailoring arthritis therapy in the wake of the NSAID crisis.

Authors:  Nancy J Olsen
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

3.  Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs.

Authors:  Xuanwen Li; Susanne Fries; Ruizhi Li; John A Lawson; Kathleen J Propert; Scott L Diamond; Ian A Blair; Garret A FitzGerald; Tilo Grosser
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

4.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

Review 5.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.

Authors:  Sven Trelle; Stephan Reichenbach; Simon Wandel; Pius Hildebrand; Beatrice Tschannen; Peter M Villiger; Matthias Egger; Peter Jüni
Journal:  BMJ       Date:  2011-01-11

6.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Authors:  Steven E Nissen; Neville D Yeomans; Daniel H Solomon; Thomas F Lüscher; Peter Libby; M Elaine Husni; David Y Graham; Jeffrey S Borer; Lisa M Wisniewski; Katherine E Wolski; Qiuqing Wang; Venu Menon; Frank Ruschitzka; Michael Gaffney; Bruce Beckerman; Manuela F Berger; Weihang Bao; A Michael Lincoff
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

7.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.

Authors:  Nigam H Shah; Paea LePendu; Anna Bauer-Mehren; Yohannes T Ghebremariam; Srinivasan V Iyer; Jake Marcus; Kevin T Nead; John P Cooke; Nicholas J Leeper
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240
  7 in total
  3 in total

1.  Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling.

Authors:  Fahad Al-Rashed; Damien Calay; Marie Lang; Clare C Thornton; Andrea Bauer; Allan Kiprianos; Dorian O Haskard; Anusha Seneviratne; Joseph J Boyle; Alex H Schönthal; Caroline P Wheeler-Jones; Justin C Mason
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

2.  A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.

Authors:  Ingrid Brænne; Christina Willenborg; Vinicius Tragante; Thorsten Kessler; Lingyao Zeng; Benedikt Reiz; Mariana Kleinecke; Simon von Ameln; Cristen J Willer; Markku Laakso; Philipp S Wild; Tanja Zeller; Lars Wallentin; Paul W Franks; Veikko Salomaa; Abbas Dehghan; Thomas Meitinger; Nilesh J Samani; Folkert W Asselbergs; Jeanette Erdmann; Heribert Schunkert
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

3.  Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.

Authors:  Antonio Buzharevski; Svetlana Paskaš; Menyhárt-Botond Sárosi; Markus Laube; Peter Lönnecke; Wilma Neumann; Blagoje Murganić; Sanja Mijatović; Danijelа Maksimović-Ivanić; Jens Pietzsch; Evamarie Hey-Hawkins
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.